319 related articles for article (PubMed ID: 12594848)
1. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein.
Welte SA; Sinzger C; Lutz SZ; Singh-Jasuja H; Sampaio KL; Eknigk U; Rammensee HG; Steinle A
Eur J Immunol; 2003 Jan; 33(1):194-203. PubMed ID: 12594848
[TBL] [Abstract][Full Text] [Related]
2. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142.
Chalupny NJ; Rein-Weston A; Dosch S; Cosman D
Biochem Biophys Res Commun; 2006 Jul; 346(1):175-81. PubMed ID: 16750166
[TBL] [Abstract][Full Text] [Related]
4. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity.
Dunn C; Chalupny NJ; Sutherland CL; Dosch S; Sivakumar PV; Johnson DC; Cosman D
J Exp Med; 2003 Jun; 197(11):1427-39. PubMed ID: 12782710
[TBL] [Abstract][Full Text] [Related]
5. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
6. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
7. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
Wittenbrink M; Spreu J; Steinle A
Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
9. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.
Eleme K; Taner SB; Onfelt B; Collinson LM; McCann FE; Chalupny NJ; Cosman D; Hopkins C; Magee AI; Davis DM
J Exp Med; 2004 Apr; 199(7):1005-10. PubMed ID: 15051759
[TBL] [Abstract][Full Text] [Related]
10. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein.
Wu J; Chalupny NJ; Manley TJ; Riddell SR; Cosman D; Spies T
J Immunol; 2003 Apr; 170(8):4196-200. PubMed ID: 12682252
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
12. ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells.
Kubin M; Cassiano L; Chalupny J; Chin W; Cosman D; Fanslow W; Müllberg J; Rousseau AM; Ulrich D; Armitage R
Eur J Immunol; 2001 May; 31(5):1428-37. PubMed ID: 11465099
[TBL] [Abstract][Full Text] [Related]
13. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.
Cosman D; Müllberg J; Sutherland CL; Chin W; Armitage R; Fanslow W; Kubin M; Chalupny NJ
Immunity; 2001 Feb; 14(2):123-33. PubMed ID: 11239445
[TBL] [Abstract][Full Text] [Related]
14. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
15. Structure of the HCMV UL16-MICB complex elucidates select binding of a viral immunoevasin to diverse NKG2D ligands.
Müller S; Zocher G; Steinle A; Stehle T
PLoS Pathog; 2010 Jan; 6(1):e1000723. PubMed ID: 20090832
[TBL] [Abstract][Full Text] [Related]
16. [Expression of NKG2D ligands on dendritic cells at different development stages and its effect on cytotoxicity of NK cells].
Tu SF; Guo KY; Hu LS; Mei JZ; Zhou J; Sun M
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):341-3, 347. PubMed ID: 18394338
[TBL] [Abstract][Full Text] [Related]
17. The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions.
Sutherland CL; Chalupny NJ; Cosman D
Immunol Rev; 2001 Jun; 181():185-92. PubMed ID: 11513139
[TBL] [Abstract][Full Text] [Related]
18. Human cytomegalovirus-encoded UL16 discriminates MIC molecules by their alpha2 domains.
Spreu J; Stehle T; Steinle A
J Immunol; 2006 Sep; 177(5):3143-9. PubMed ID: 16920952
[TBL] [Abstract][Full Text] [Related]
19. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.
Schrama D; Terheyden P; Otto K; Kämmerer U; Bröcker EB; Lühder F; Cosman D; Andersen MH; Becker JC
Eur J Immunol; 2006 Jan; 36(1):65-72. PubMed ID: 16342232
[TBL] [Abstract][Full Text] [Related]
20. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
